Guangbi Yao

Summary

Country: China

Publications

  1. ncbi request reprint [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients]
    Mei Zhu
    Clinical Immunology Research Center, Jing an Qu Central Hospital, Shanghai 200040, China
    Zhonghua Gan Zang Bing Za Zhi 13:534-6. 2005
  2. ncbi request reprint Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naive Chinese chronic hepatitis B patients
    G B Yao
    Clinical Immunology Research Center, Department of Gastroenterology and Hepatology, Shanghai Jing An Central Hospital, Shanghai, China
    J Viral Hepat 17:51-8. 2010
  3. ncbi request reprint [Results of 3 years of continuous entecavir treatment in nucleos(t)ide-naive chronic hepatitis B patients]
    Guang Bi Yao
    Clinical Immunology Research Center, Department of Gastroenterology and Hepatology, Shanghai Jing anqu Central Hospital, Shanghai 200040, China
    Zhonghua Gan Zang Bing Za Zhi 17:881-6. 2009
  4. pmc Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China
    Guangbi Yao
    Immunology Disease Department, Shanghai Jing An Central Hospital, No 259 Xikang Road, Shanghai, 200040, P R China
    Hepatol Int 1:373-81. 2007
  5. pmc Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study
    Guangbi Yao
    Shanghai Jing An Qu Central Hospital, No 259 Xikang Road, Shanghai, 200040, China
    Hepatol Int 2:486-93. 2008
  6. doi request reprint A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China
    Guang Bi Yao
    Beijing Ditan Hospital, Beijing, China
    J Dig Dis 10:131-7. 2009
  7. ncbi request reprint Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China
    Guangbi Yao
    Clinical Immunology Research Center, Department of Gastroenterology and Hepatology, Shanghai Jing An Central Hospital, No 259 Xikang Road, Shanghai PR200040, China
    J Antimicrob Chemother 60:201-5. 2007
  8. ncbi request reprint [A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B]
    Guang Bi Yao
    Clinical Immunology Research Center, Shanghai Jing An Qu Central Hospital, Shanghai 200040, China
    Zhonghua Nei Ke Za Zhi 45:891-5. 2006
  9. ncbi request reprint [Standardize the prevention and management practice of hepatitis B: comment on the Chinese 2005 guideline for hepatitis B infection]
    Guang Bi Yao
    Zhonghua Nei Ke Za Zhi 45:885-6. 2006
  10. ncbi request reprint An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B
    Guangbi Yao
    Clinical Immunology Centre, Jing san Qu Central Hospital, Shanghai 200040, China
    Chin Med J (Engl) 115:1814-8. 2002

Collaborators

Detail Information

Publications18

  1. ncbi request reprint [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients]
    Mei Zhu
    Clinical Immunology Research Center, Jing an Qu Central Hospital, Shanghai 200040, China
    Zhonghua Gan Zang Bing Za Zhi 13:534-6. 2005
    ..To investigate the factors which may affect the rate of HBeAg seroconversion and its durability after long-term lamivudine therapy in chronic hepatitis B patients...
  2. ncbi request reprint Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naive Chinese chronic hepatitis B patients
    G B Yao
    Clinical Immunology Research Center, Department of Gastroenterology and Hepatology, Shanghai Jing An Central Hospital, Shanghai, China
    J Viral Hepat 17:51-8. 2010
    ..The results are consistent with the findings using entecavir globally and in Japan...
  3. ncbi request reprint [Results of 3 years of continuous entecavir treatment in nucleos(t)ide-naive chronic hepatitis B patients]
    Guang Bi Yao
    Clinical Immunology Research Center, Department of Gastroenterology and Hepatology, Shanghai Jing anqu Central Hospital, Shanghai 200040, China
    Zhonghua Gan Zang Bing Za Zhi 17:881-6. 2009
    ..To evaluate the virological, serological and biochemical outcomes of 3 years of entecavir (ETV) treatment in nucleoside-naive chronic hepatitis B patients...
  4. pmc Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China
    Guangbi Yao
    Immunology Disease Department, Shanghai Jing An Central Hospital, No 259 Xikang Road, Shanghai, 200040, P R China
    Hepatol Int 1:373-81. 2007
    ..This randomized, double-blind, placebo-controlled study was undertaken to evaluate the efficacy and safety of entecavir in Chinese patients with lamivudine-refractory chronic hepatitis B...
  5. pmc Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study
    Guangbi Yao
    Shanghai Jing An Qu Central Hospital, No 259 Xikang Road, Shanghai, 200040, China
    Hepatol Int 2:486-93. 2008
    ..We evaluated the effect of continued entecavir and lamivudine treatment in patients who continued treatment in year 2 and the off-treatment durability of patients who achieved a protocol-defined consolidated response at week 48...
  6. doi request reprint A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China
    Guang Bi Yao
    Beijing Ditan Hospital, Beijing, China
    J Dig Dis 10:131-7. 2009
    ..To evaluate the long-term efficacy and safety of lamivudine treatment for chronic hepatitis B and the impact of emergence of YMDD mutation of hepatitis B virus (HBV)...
  7. ncbi request reprint Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China
    Guangbi Yao
    Clinical Immunology Research Center, Department of Gastroenterology and Hepatology, Shanghai Jing An Central Hospital, No 259 Xikang Road, Shanghai PR200040, China
    J Antimicrob Chemother 60:201-5. 2007
    ..The results of these studies suggest that entecavir should be recommended as a first-line choice among the currently available anti-HBV nucleos(t)ides...
  8. ncbi request reprint [A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B]
    Guang Bi Yao
    Clinical Immunology Research Center, Shanghai Jing An Qu Central Hospital, Shanghai 200040, China
    Zhonghua Nei Ke Za Zhi 45:891-5. 2006
    ..This study was to evaluate the antiviral efficacy and safety in nucleoside naive Chinese patients with chronic hepatitis B (CHB) treated with entecavir (ETV) or lamivadine (LVD)...
  9. ncbi request reprint [Standardize the prevention and management practice of hepatitis B: comment on the Chinese 2005 guideline for hepatitis B infection]
    Guang Bi Yao
    Zhonghua Nei Ke Za Zhi 45:885-6. 2006
  10. ncbi request reprint An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B
    Guangbi Yao
    Clinical Immunology Centre, Jing san Qu Central Hospital, Shanghai 200040, China
    Chin Med J (Engl) 115:1814-8. 2002
    ..To evaluate the long-term efficacy and safety of lamivudine therapy for the treatment of chronic hepatitis B and the clinical influence of emergence of tyrosine methionine aspartic acid (YMDD) motif mutation of hepatitis B virus (HBV)...
  11. ncbi request reprint [A study of the dosage and efficacy of entecavir for treating hepatitis B virus]
    Guang Bi Yao
    Central Hospital of Jing an District, Shanghai 200040, China
    Zhonghua Gan Zang Bing Za Zhi 13:484-7. 2005
    ..To evaluate the antiviral activity and safety of entecavir in patients with chronic HBV infection as a preliminarily step in selecting 0.1 mg or 0.5 mg as a better dosage for a further large scale clinical trial...
  12. ncbi request reprint A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B
    Guang Bi Yao
    Shanghai Jing An Qu Central Hospital, Shanghai 200040, China
    Hepatobiliary Pancreat Dis Int 3:188-93. 2004
    ..This clinical trial was to evaluate the long-term efficacy and safety of 3-year lamivudine treatment for chronic hepatitis B and the impact of emergence of YMDD mutation of hepatitis B virus (HBV)...
  13. ncbi request reprint A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B
    Minde Zeng
    Renji Hospital, Shanghai, China
    Hepatology 44:108-16. 2006
    ..The study is continuing for an additional 4 years with all subjects on open-label ADV 10 mg daily...
  14. ncbi request reprint [The long-term efficacy of lamivudine in chronic hepatitis B: interim analysis of 3-year's clinical course]
    Guang Bi Yao
    Shanghai Jing An Qu Central Hospital, Shanghai 200040, China
    Zhonghua Nei Ke Za Zhi 42:382-7. 2003
    ..To evaluate the long-term efficacy and safety of 3-year lamivudine treatment for chronic hepatitis B and the impact of emergence of YMDD mutation of hepatitis B virus (HBV)...
  15. ncbi request reprint [Efficacy and safety in chronic hepatitis B adolescent patients with lamivudine therapy]
    Wei lun Lu
    Department of Infectious Disease, Third Affiliated Hospital of Sun Yat Sen University, Guangzhou 510630, China
    Zhonghua Gan Zang Bing Za Zhi 12:429-31. 2004
    ..To analysis the efficacy and safety of lamivudine (made in China) therapy for 52 weeks in adolescent patients with chronic hepatitis B (CHB)...
  16. ncbi request reprint Long-term safety of lamivudine treatment in patients with chronic hepatitis B
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, 48109 0362, USA
    Gastroenterology 125:1714-22. 2003
    ..The aim of this analysis was to determine the incidence of hepatitis flares, hepatic decompensation, and liver-disease-related (LDR) serious adverse events (SAE) during long-term lamivudine treatment...
  17. ncbi request reprint [Liver histological changes after lamivudine treating in chronic hepatitis B patients with HBeAg positive]
    Rong hua Jin
    Beijing Youan Hospital, Beijing 100054, China
    Zhonghua Gan Zang Bing Za Zhi 11:555-7. 2003
    ..To investigate the histological changes in liver biopsy tissues taken from chronic hepatitis B patients with HBsAg and HBeAg positive and ALT abnormal after lamivudine therapy for one year...
  18. ncbi request reprint [Focusing on the diagnosis and treatment of autoimmune hepatitis in China]
    Guang Bi Yao
    Zhonghua Gan Zang Bing Za Zhi 13:1-2. 2005